Message From CSO & R&D President
 
Disease Areas of Focus
 
Overview
Cancer
Atherosclerosis/ Thrombosis
Diabetes
Obesity
Psychiatric Disorders
Alzheimer's Disease
Hepatitis
HIV/AIDS
Rheumatoid Arthritis
Solid Organ Transplant Rejection
 
Recent Accomplishments
 
Pipeline
 
Biologics
 
R&D Facts
 
Clinical Trials Disclosure

 

  » BMS.com Home » Pharmaceutical Research & Development » Disease Areas of Focus » Psychiatric Disorders
SEARCH INDEX
 

Pharmaceutical Research & Development


Disease Areas of Focus

Psychiatric Disorders

An estimated 26.2 percent of Americans ages 18 and older—about one in four adults—suffer from a diagnosable mental disorder, or psychiatric disorder, in a given year.1 In addition, mental disorders are the leading cause of disability for ages 15-44.2 These illnesses can be extremely debilitating. For example, affective disorders, one type of psychiatric illness, is characterized by disturbances of mood such as anxiety, depression, or elation and can interfere with many aspects of life.

While there are various drugs available for psychiatric illnesses, they often do not achieve significant efficacy or they produce troublesome side effects. Bristol-Myers Squibb has contributed to the treatment of psychiatric disorders with two new products since 2002 and continues to pursue new treatments that are both highly effective and safe.

Back to Disease Areas

 

1. R. C. Kessler, W. T. Chiu, O. Demler, E. E. Walters. Prevalence, severity, and co-morbidity of twelve-month DSM-IV disorders in the National Co-morbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun;62(6):617-27.

2. The World Health Organization. The World Health Report 2004: Changing History, Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Geneva: WHO, 2004.




[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.